Median OS after osimertinib progression (osimertinib given as second‐line in EGFR T790M mutant NSCLC patents) was 5.4 months in 40 patients from the AURA study, whose plasma was available after disease progression [100]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.